These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 16651443)

  • 1. Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2.
    Wu J; Lee C; Yokom D; Jiang H; Cheang MC; Yorida E; Turbin D; Berquin IM; Mertens PR; Iftner T; Gilks CB; Dunn SE
    Cancer Res; 2006 May; 66(9):4872-9. PubMed ID: 16651443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy.
    Stratford AL; Habibi G; Astanehe A; Jiang H; Hu K; Park E; Shadeo A; Buys TP; Lam W; Pugh T; Marra M; Nielsen TO; Klinge U; Mertens PR; Aparicio S; Dunn SE
    Breast Cancer Res; 2007; 9(5):R61. PubMed ID: 17875215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers.
    Fujii T; Kawahara A; Basaki Y; Hattori S; Nakashima K; Nakano K; Shirouzu K; Kohno K; Yanagawa T; Yamana H; Nishio K; Ono M; Kuwano M; Kage M
    Cancer Res; 2008 Mar; 68(5):1504-12. PubMed ID: 18316615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Y-box-binding protein 1 confers EGF independence to human mammary epithelial cells.
    Berquin IM; Pang B; Dziubinski ML; Scott LM; Chen YQ; Nolan GP; Ethier SP
    Oncogene; 2005 Apr; 24(19):3177-86. PubMed ID: 15735691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting YB-1 in HER-2 overexpressing breast cancer cells induces apoptosis via the mTOR/STAT3 pathway and suppresses tumor growth in mice.
    Lee C; Dhillon J; Wang MY; Gao Y; Hu K; Park E; Astanehe A; Hung MC; Eirew P; Eaves CJ; Dunn SE
    Cancer Res; 2008 Nov; 68(21):8661-6. PubMed ID: 18974106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The transcriptional induction of PIK3CA in tumor cells is dependent on the oncoprotein Y-box binding protein-1.
    Astanehe A; Finkbeiner MR; Hojabrpour P; To K; Fotovati A; Shadeo A; Stratford AL; Lam WL; Berquin IM; Duronio V; Dunn SE
    Oncogene; 2009 Jun; 28(25):2406-18. PubMed ID: 19430491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Y-box binding protein 1 is up-regulated in proliferative breast cancer and its inhibition deregulates the cell cycle.
    Yu YN; Yip GW; Tan PH; Thike AA; Matsumoto K; Tsujimoto M; Bay BH
    Int J Oncol; 2010 Aug; 37(2):483-92. PubMed ID: 20596676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
    Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
    Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The phosphoinositide-dependent kinase-1 inhibitor 2-amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-acetamide (OSU-03012) prevents Y-box binding protein-1 from inducing epidermal growth factor receptor.
    To K; Zhao Y; Jiang H; Hu K; Wang M; Wu J; Lee C; Yokom DW; Stratford AL; Klinge U; Mertens PR; Chen CS; Bally M; Yapp D; Dunn SE
    Mol Pharmacol; 2007 Sep; 72(3):641-52. PubMed ID: 17595327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of nuclear YB-1 localization with lung resistance-related protein and epidermal growth factor receptor expression in lung cancer.
    Hyogotani A; Ito K; Yoshida K; Izumi H; Kohno K; Amano J
    Clin Lung Cancer; 2012 Sep; 13(5):375-84. PubMed ID: 22284440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel.
    Fujita T; Ito K; Izumi H; Kimura M; Sano M; Nakagomi H; Maeno K; Hama Y; Shingu K; Tsuchiya S; Kohno K; Fujimori M
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8837-44. PubMed ID: 16361573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 Suppresses lung resistance-related protein expression through Y-box binding protein 1 in the MCF-7 breast tumor cell line.
    Tian B; Liu J; Liu B; Dong Y; Liu J; Song Y; Sun Z
    J Cell Physiol; 2011 Dec; 226(12):3433-41. PubMed ID: 21344396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of c-ErbB1/epidermal growth factor receptor and c-ErbB2/HER-2 expression in bronchial dysplasia: evaluation of potential targets for chemoprevention of lung cancer.
    Merrick DT; Kittelson J; Winterhalder R; Kotantoulas G; Ingeberg S; Keith RL; Kennedy TC; Miller YE; Franklin WA; Hirsch FR
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2281-8. PubMed ID: 16609045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
    Huang Y; Li X; Jiang J; Frank SJ
    Oncogene; 2006 Dec; 25(58):7565-76. PubMed ID: 16785991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel mechanism for integrin-mediated ras activation in breast carcinoma cells: the alpha6beta4 integrin regulates ErbB2 translation and transactivates epidermal growth factor receptor/ErbB2 signaling.
    Yoon SO; Shin S; Lipscomb EA
    Cancer Res; 2006 Mar; 66(5):2732-9. PubMed ID: 16510594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.
    Massarweh S; Osborne CK; Jiang S; Wakeling AE; Rimawi M; Mohsin SK; Hilsenbeck S; Schiff R
    Cancer Res; 2006 Aug; 66(16):8266-73. PubMed ID: 16912207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear Y-box-binding protein-1 is a poor prognostic marker and related to epidermal growth factor receptor in uterine cervical cancer.
    Nishio S; Ushijima K; Yamaguchi T; Sasajima Y; Tsuda H; Kasamatsu T; Kage M; Ono M; Kuwano M; Kamura T
    Gynecol Oncol; 2014 Mar; 132(3):703-8. PubMed ID: 24486603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor.
    Witters LM; Witkoski A; Planas-Silva MD; Berger M; Viallet J; Lipton A
    Oncol Rep; 2007 Feb; 17(2):465-9. PubMed ID: 17203189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of BRCA1, HER-1 (EGFR) and HER-2 in sporadic breast cancer and relationships to other clinicopathological prognostic features.
    Ansquer Y; Mandelbrot L; Lehy T; Salomon L; Dhainaut C; Madelenat P; Feldmann G; Walker F
    Anticancer Res; 2005; 25(6C):4535-41. PubMed ID: 16334138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of KIT, EGFR, HER-2 and tyrosine phosphorylation in undifferentiated thyroid carcinoma: implication for a new therapeutic approach.
    Murakawa T; Tsuda H; Tanimoto T; Tanabe T; Kitahara S; Matsubara O
    Pathol Int; 2005 Dec; 55(12):757-65. PubMed ID: 16287490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.